Prosonix has launched a co-crytsallisation service for the production of APIs for inhalable drugs and oral medicines.
The new service will offer Prosonix’ range of ultrasound assisted processing and production technologies to drug industry customers wishing to develop co-crystallisation for industrial-scale application.
CTO Grahm Ruecroft told in-pharmatechnologist that standard preparation of co-crystals is not straightforward, explaining that: “They are typically prepared by melt-crystallization, solid state grinding and re-crystallization from solvents.
“Conversely,” Dr Ruecroft continued “[adding] ultrasound assisted crystallization to a co-crystallization system helps the rapid formation of the co-crystal phase at the expense of the unwanted fractional crystallization of the API and or co-crystal former, and moreover helps overcome some inherently slow kinetics.”
“For these reasons it seemed appropriate that Prosonix should offer a specific service relating to co-crystal processing and development using the technologies at its disposal whilst differentiating this service from its other activities.”
Demand for better production methods for inhalable and oral drugs was also a driver for new offering according to Ruecroft, who added that Prosonix already has experience of conducting co-crystallisation in this field.
“In May 2009, the company and Prof. Rob Price of the Department of Pharmacy and Pharmacology, Uuniversity of Bath, received a research grant of £190,500 to develop methodology and identify new processing technology for the manufacture of pharmaceutical co-crystals and binary API crystals suitable for use in inhaled and oral medicines. “